IPCI has been the topic of a number of other research reports. Maxim Group set a $6.00 price target on Intellipharmaceutics International and gave the stock a buy rating in a research note on Thursday, October 6th. Zacks Investment Research cut Intellipharmaceutics International from a hold rating to a sell rating in a research note on Thursday, October 13th.
Shares of Intellipharmaceutics International (NASDAQ:IPCI) traded down 1.82% during mid-day trading on Monday, reaching $2.70. 81,018 shares of the company’s stock traded hands. The company’s market capitalization is $77.62 million. Intellipharmaceutics International has a 1-year low of $1.41 and a 1-year high of $3.33. The firm has a 50-day moving average price of $2.12 and a 200-day moving average price of $1.87.
Intellipharmaceutics International (NASDAQ:IPCI) last issued its quarterly earnings results on Friday, October 14th. The company reported ($0.07) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.07). Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 371.11%. On average, equities research analysts forecast that Intellipharmaceutics International will post ($0.28) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Intellipharmaceutics International stock. Atria Investments LLC raised its stake in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) by 12.1% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 75,895 shares of the company’s stock after buying an additional 8,168 shares during the period. Atria Investments LLC owned about 0.26% of Intellipharmaceutics International worth $159,000 as of its most recent filing with the SEC. 1.34% of the stock is owned by institutional investors.
About Intellipharmaceutics International
IntelliPharmaCeutics International Inc is a Canada-based pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.